| Literature DB >> 35890373 |
You Zhou1,2, Mulan Mo1, Dexu Luo1, Yi Yang1, Jialin Hu1, Chenqing Ye2, Longxiang Lin3, Chuanshan Xu1, Wenjie Chen1,4,5.
Abstract
5-aminolevulinic acid (5-ALA) has been extensively studied for its sustainability and broad-spectrum applications in medical research and theranostics, as well as other areas. It's a precursor of protoporphyrin IX (PpIX), a sustainable endogenous and naturally-existing photosensitizer. However, to the best of our knowledge, a scientometrics study based on the scientific knowledge assay of the overall situation on 5-ALA research has not been reported so far, which would be of major importance to the relevant researchers. In this study, we collected all the research articles published in the last two decades from the Web of Science Core Collection database and employed bibliometric methods to comprehensively analyze the dataset from different perspectives using CiteSpace. A total of 1595 articles were identified. The analysis results showed that China published the largest number of articles, and SBI Pharmaceuticals Co., Ltd. was the most productive institution that sponsored several of the most productive authors. The cluster analysis and burst detections indicated that the improvement of photodynamic efficacy theranostics is the up-to-date key direction in 5-ALA research. Furthermore, we emphatically studied nanotechnology involvement in 5-ALA delivery and theranostics research. We envision that our results will be beneficial for researchers to have a panorama of and deep insights into this area, thus inspiring further exploitations, especially of the nanomaterial-based systems for 5-ALA delivery and theranostic applications.Entities:
Keywords: 5-aminolevulinic acid (5-ALA); CiteSpace; bibliometric analysis; nanotechnology
Year: 2022 PMID: 35890373 PMCID: PMC9320574 DOI: 10.3390/pharmaceutics14071477
Source DB: PubMed Journal: Pharmaceutics ISSN: 1999-4923 Impact factor: 6.525
Figure 1The flow chart of bibliometric analysis and basic profile of 5-ALA research. (A) The flowchart of bibliometric analysis mentioned in methods section. (B) The annual distributions of 5-ALA publications and their citations.
Figure 2Contributions of different countries and institutions. (A) The exhibition of countries in the geographical map with publication counts. (B) The evolution trends of publications and citations of four major countries. Solid line indicates publications and dotted line indicates citations. (C) Co-occurrence network of countries analyzed by CiteSpace. (D) The graph of publication number, h-index, and ACI of the top-10 most active institutions. (E) Cooperation network of institutions analyzed by CiteSpace.
The information of the top-20 countries according to the publication analysis in 5-ALA research.
| Rank | Country | Between Centrality | Publications | % of 1595 | Times Cited | ACI | |
|---|---|---|---|---|---|---|---|
| 1 | China | 0.14 | 445 | 27.88 | 39 | 6763 | 15.05 |
| 2 | Japan | 0.19 | 325 | 20.36 | 35 | 4986 | 15.17 |
| 3 | United States | 0.05 | 246 | 15.41 | 36 | 4858 | 19.52 |
| 4 | Germany | 0.14 | 147 | 9.21 | 37 | 6314 | 42.50 |
| 5 | South Korea | 0.00 | 69 | 4.32 | 18 | 907 | 12.00 |
| 6 | United Kingdom | 0.65 | 64 | 4.14 | 22 | 1252 | 19.56 |
| 7 | Brazil | 0.19 | 51 | 3.19 | 18 | 833 | 16.33 |
| 8 | Italy | 0.05 | 44 | 2.76 | 14 | 611 | 13.89 |
| 9 | Switzerland | 0.37 | 40 | 2.51 | 18 | 1158 | 28.95 |
| 10 | Pakistan | 0.31 | 38 | 2.38 | 20 | 1299 | 34.18 |
| 11 | Austria | 0.01 | 36 | 2.26 | 14 | 859 | 23.86 |
| 12 | Spain | 0.08 | 35 | 2.19 | 14 | 641 | 18.31 |
| 13 | Norway | 0.14 | 28 | 1.75 | 12 | 526 | 18.79 |
| 14 | Netherlands | 0.23 | 26 | 1.63 | 16 | 630 | 24.23 |
| 15 | Canada | 0.14 | 24 | 1.51 | 14 | 819 | 34.13 |
| 16 | France | 0.54 | 24 | 1.51 | 10 | 253 | 10.54 |
| 17 | Poland | 0.05 | 24 | 1.51 | 8 | 168 | 7.00 |
| 18 | Turkey | 0.00 | 22 | 1.38 | 8 | 214 | 9.73 |
| 19 | Iran | 0.00 | 21 | 1.32 | 8 | 204 | 9.71 |
| 20 | Russia | 0.22 | 21 | 1.32 | 8 | 175 | 8.33 |
Top 11 most active journals in the field of 5-ALA research.
| Journal | Publisher’s Country | Publication Counts | ACI | Categories | Quartile in Category | 5-Year Impact Factor | |
|---|---|---|---|---|---|---|---|
|
| Netherlands | 165 | 8.73 | Oncology | 3 | 3.60 | 19 |
|
| Switzerland | 38 | 16.08 | Biophysics; Biochemistry & Molecular Biology | 1 | 5.38 | 16 |
|
| United States | 31 | 41.97 | Clinical Neurology; Surgery | 1 | 5.15 | 18 |
|
| United States | 28 | 22.25 | Dermatology; Surgery | 1 | 3.38 | 14 |
|
| United States | 25 | 28.76 | Multidisciplinary Sciences | 2 | 3.79 | 15 |
|
| United States | 23 | 23.00 | Biophysics; Biochemistry & Molecular Biology | 2; 3 | 3.06 | 15 |
|
| Denmark | 23 | 13.96 | Dermatology | 2 | 3.16 | 12 |
|
| England | 22 | 15.00 | Multidisciplinary Sciences | 1 | 5.13 | 10 |
|
| United States | 21 | 10.38 | Surgery; Clinical Neurology | 3; 4 | 2.32 | 7 |
|
| Austria | 20 | 28.30 | Surgery; Clinical Neurology; | 3; 4 | 2.47 | 11 |
|
| United States | 20 | 19.25 | Clinical Neurology; Oncology | 2; 3 | 4.23 | 11 |
Figure 3The analysis of 5-ALA research publishers and authors. (A) The numbers for top-10 most relevant subject categories for publications. (B) Co-citation network of journals analyzed by CiteSpace. (C) The publications, h-index, and ACI of top-11 productive authors. (D) Cooperation network of authors analyzed by CiteSpace. (E) Co-citation network of authors analyzed by CiteSpace.
Top-10 most cited literatures in the field of 5-ALA.
| Title | First Author | Journal | Publication Year | Total Citations |
|---|---|---|---|---|
| Fluorescence-guided surgery with 5-aminolevulinic acid for resection of malignant glioma: a randomised controlled multicentre phase III trial [ | Stummer, Walter |
| 2006 | 2032 |
| Counterbalancing risks and gains from extended resections in malignant glioma surgery: a supplemental analysis from the randomized 5-aminolevulinic acid glioma resection study Clinical article [ | Stummer, Walter |
| 2011 | 198 |
| Clinically relevant reduction in risk of recurrence of superficial bladder cancer using 5-aminolevulinic acid-induced fluorescence diagnosis: 8-year results of prospective randomized study [ | Denzinger, Stefan |
| 2007 | 198 |
| Co-registered fluorescence-enhanced tumor resection of malignant glioma: relationships between delta-aminolevulinic acid-induced protoporphyrin IX fluorescence, magnetic resonance imaging enhancement, and neuropathological parameters Clinical article [ | Roberts, David W |
| 2011 | 190 |
| 5-Aminolevulinic Acid-derived Tumor Fluorescence: The Diagnostic Accuracy of Visible Fluorescence Qualities as Corroborated by Spectrometry and Histology and Postoperative Imaging [ | Stummer, Walter |
| 2014 | 171 |
| Photodynamic therapy of acne vulgaris using 5-aminolevulinic acid versus methyl aminolevulinate [ | Wiegell, Stine Regin |
| 2006 | 151 |
| Study on physicochemical properties of ionic liquids based on alanine [C(n)mim] [Ala] ( | Fang, Da-Wei |
| 2008 | 149 |
| Novel development of 5-aminolevurinic acid (ALA) in cancer diagnoses and therapy [ | Ishizuka, Masahiro |
| 2011 | 145 |
| Effects of 5-aminolevulinic acid on oilseed rape seedling growth under herbicide toxicity stress [ | Zhang, Wufeng |
| 2008 | 141 |
| 5-Aminolevulinic Acid Is a Promising Marker for Detection of Anaplastic Foci in Diffusely Infiltrating Gliomas with Nonsignificant Contrast Enhancement [ | Widhalm, Georg |
| 2010 | 134 |
The top-30 keywords with the largest occurrence times.
| Rank | Keywords | Counts | Centrality | Rank | Keywords | Counts | Centrality |
|---|---|---|---|---|---|---|---|
| 1 | 5 Aminolevulinic acid | 388 | 0.00 | 16 | Cell | 77 | 0.09 |
| 2 | Photodynamic therapy | 230 | 0.00 | 17 | Therapy | 74 | 0.03 |
| 3 | Cancer | 143 | 0.01 | 18 | Surgery | 72 | 0.03 |
| 4 | Protoporphyrin ix | 124 | 0.06 | 19 | Survival | 68 | 0.02 |
| 5 | Expression | 123 | 0.05 | 20 | Growth | 67 | 0.01 |
| 6 | In vitro | 118 | 0.05 | 21 | Extent | 60 | 0.03 |
| 7 | Fluorescence | 111 | 0.02 | 22 | Induced protoporphyrin ix | 59 | 0.12 |
| 8 | Delta aminolevulinic acid | 108 | 0.02 | 23 | Biosynthesis | 59 | 0.11 |
| 9 | Malignant glioma | 107 | 0.23 | 24 | Carcinoma | 56 | 0.13 |
| 10 | Resection | 105 | 0.04 | 25 | Skin | 50 | 0.02 |
| 11 | Tumor | 93 | 0.03 | 26 | Light | 47 | 0.04 |
| 12 | Accumulation | 89 | 0.11 | 27 | Heme | 43 | 0.03 |
| 13 | Mechanism | 85 | 0.07 | 28 | Oxidative stress | 43 | 0.25 |
| 14 | Glioblastoma Multiforme | 80 | 0.00 | 29 | Delivery | 38 | 0.08 |
| 15 | Apoptosis | 78 | 0.05 | 30 | Diagnosis | 38 | 0.18 |
Figure 4Research topics of 5-ALA research related photodiagnosis/photodynamic therapy. (A) Co-occurrence network of keywords in this field analyzed by CiteSpace. (B) Major research topics clustered by CiteSpace. (C) The annual changes of 5-ALA based photodiagnosis/photodynamic therapy publication. Data were achieved in the retrieve formula of TI = (*aminolevulinic acid OR 5-ALA) AND TS = (photodiagnosis OR photodynamic) and articles only.
Figure 5Hotspots and frontiers in 5-ALA research field. (A) The top-25 keywords with strongest citation burst detected by CiteSpace. (B) The top-25 authors with strongest citation burst detected by CiteSpace.
Figure 6Key information for nanomaterials combined 5-ALA research. (A) The trends of 5-ALA-based and PpIX-based annual publication numbers. Data were collected in the retrieval formula of TI = (*aminolevulinic acid OR 5 ALA) and TS = (nano*), and TS = (Protoporphyrin ix OR PpIX) and TS = (nano*) respectively, publications were articles only. (B) Cluster analysis diagram of nanomaterials combined 5-ALA research by CiteSpace.